Baxter falls despite double beat, boosting guidance (BAX:NYSE)

Baxter (BAX) reported Q3 2026 sales of $3B, up 5%, and raised full-year guidance. Adjusted EPS was $0.58, exceeding expectations. The company highlighted progress in strategic priorities, including business stabilization, balance sheet strengthening, and continuous improvement. Baxter GPS initiatives drove operational improvements, and the company announced plans to discontinue cephalosporin production.

Baxter International (BAX) raised its 2026 outlook, projecting 3-4% organic sales growth and adjusted EPS of $2.05-$2.15. CEO Andrew Hider cited Q3 performance as evidence of a turnaround. The company also targets ~3x net leverage.

Baxter International (NYSE:BAX) reported Q3 2026 net sales of $3.0B, up 5%, and adjusted EPS of $0.58, beating estimates. Shares fell 5.2% premarket due to margin concerns. Medical Products & Therapies grew 6%, while Healthcare Systems & Technologies grew 4%. Adjusted gross margin declined 110 bps YoY to 38.3%. Baxter raised full-year guidance, targeting 3-4% organic sales growth and $2.05-$2.15 adjusted EPS.

Baxter (BAX) reported Q3 2026 revenue of $2.98B, beating estimates by 2.3%, with adjusted EPS of $0.58, an 11.9% beat. Adjusted operating income was $432M, a 7.2% beat. The company raised its full-year adjusted EPS guidance to $2.10 at the midpoint. Operating and free cash flow margins improved year-over-year.

Baxter International (BAX) reported Q3 net income of $294M, up from a $46M loss last year. EPS from continuing ops was $0.57, with adjusted EPS at $0.58, down 16%. Sales rose 5% to $2.98B. The company raised its 2026 outlook, expecting adjusted EPS of $2.05-$2.15 and sales growth of 4-5%. Shares gained 2.12% in pre-market trading.

Baxter (BAX) reported Q3 EPS of $0.58, beating estimates by $0.06, with revenue at $2.98B, exceeding expectations. The company forecasts FY 2026 EPS of $2.05-$2.15. BAX stock is down 2.68% over 3 months but up 32.88% year-over-year.